Cabaletta Bio Inc

NASDAQ:CABA   3:59:44 PM EDT
14.86
-0.17 (-1.13%)
Regulatory, Other Pre-Announcement

Cabaletta Bio Reports Third Quarter 2020 Financial Results And Provides Business Update

Published: 11/10/2020 13:13 GMT
Cabaletta Bio Inc (CABA) - Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update.
Cabaletta Bio Inc - Expects Cash, Cash Equivalents & Investments As of Sept 30, 2020 Will Enable Co to Fund Operating Plan Through at Least Q3 of 2022.
Cabaletta Bio Inc Qtrly Loss per Share $0.36.
Cabaletta Bio Inc - Expects to Report Acute Safety Data From Initial Cohort in Phase 1 Clinical Trial Study in First Half of 2021.
Cabaletta Bio Inc- an Ind Submission to FDA Anticipated in H2 of 2021 for Treatment for Musk-associated Myasthenia Gravis.